http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0033503-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-515 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-335 |
| filingDate | 1981-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1986-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1986-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0033503-B1 |
| titleOfInvention | Medicaments with cytostatic activity and use of cyclic compounds, in which the heterocyclic n-ring atoms are substituted by several glycidyl groups, in pharmaceutical compositions |
| abstract | For the contracting States : BE CH DE FR GB IT LI NL SE 1. Cytostatic medicinal preparations based on polyglycidyl-substituted N-heterocyclic organic ring compounds, characterized in that they contain in one heterocyclic ring or in two interconnected heterocyclic rings, which either have one or two ring members in common or are attached to one another by a bridge member, at least two ring segments corresponding to the following formula see diagramm : EP0033503,P26,F1 or at least one ring segment corresponding to the following formula see diagramm : EP0033503,P26,F2 in which the glycidyl residue corresponds to the following formula see diagramm : EP0033503,P26,F3 in which R is hydrogen or the methyl group, and in that, providing these ring segments are not themselves closed to form the ring, they further contain carbon and, optionally, nitrogen as ring-closing elements and in that they may contain halogens or unsubstituted hydrocarbon radicals containing no more than 8 C-atoms as further substituents on the heterocyclic rings, isocyanurates, urazoles and hydantoins being excluded as heterocycles and the polyglycidyl-substituted N-heterocycles present therein not exceeding a molecular weight of 1000. For the contracting State : AT 1. A process for the production of cytostatic medicinal preparation based on polyglicidyl-substituted N-heterocyclic organic ring compounds, characterized in that the polyglicidyl-substituted N-heterocyclic organic ring compounds contain in one heterocyclic ring or in two interconnected heterocyclic rings, which either have one or two ring members in common or are attached to one another by a bridge member, at least two ring segments corresponding to the following formula see diagramm : EP0033503,P29,F1 or at least one ring segment corresponding to the following formula see diagramm : EP0033503,P29,F2 in which the glycidyl residue corresponds to the following formula see diagramm : EP0033503,P29,F3 in which R is hydrogen or the methyl group, and in that, providing these ring segments are not themselves closed to form the ring, they further contain carbon and, optionally, nitrogen as ring-closing elements and in that they may contain halogens or unsubstituted hydrocarbon radicals containing no more than 8 C-atoms as further substituents on the heterocyclic rings, isocyanurates, urazoles and hydantoins being excluded as heterocycles and the polyglycidyl-substituted N-heterocycles present therein not exceeding a molecular weight of 1000. |
| priorityDate | 1980-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 176.